A multicentre, randomised, phase II study of hypofractionated bladder radiotherapy with or without image guided adaptive planning
Disease site: Bladder cancer, urological cancers
Treatment modality: Radiotherapy
Status: In follow-up
HYBRID is a multicentre, phase II, randomised controlled trial to assess whether image guided adaptive planning radiotherapy techniques can lead to a reduction in the level of acute non genitourinary side effects experienced by patients with muscle invasive bladder cancer unsuitable for daily radical radiotherapy.
62 patients will be recruited from UK sites over 2 years. All patients will receive weekly hypofractionated radiotherapy for 6 weeks and will be randomised between either standard or adaptive planning. Patients in the adaptive planning group will have three radiotherapy plans generated and a CT scan prior to each treatment delivery will be used to select the most appropriate plan of the day, adapting to variations in bladder position. Participants will be followed up at regular intervals for 24 months, and then annually thereafter.
Chief Investigator: Dr Robert Huddart, The Royal Marsden NHS Foundation Trust
ICR-CTSU Scientific Lead: Dr Emma Hall
Trial management contact: [email protected]
Sponsor: The Institute of Cancer Research
Funding: Cancer Research UK (CRUK/12/055)
Further information including recruitment progress is available from the following link:
UK Clinical Trials Gateway
Patient friendly information is available from the following link:
Publications and presentations
Huddart R, McDonald F, Lewis R, Hall E. HYBRID – evaluating new radiation technology in patients with unmet needs. Clin Oncol (R Coll Radiol). 2013; 25(9); 546-548.